First Ozempic, then tirzepitide, so what's next?
Retatrutide
Both Ozempic and Wegovy are semaglutide, a GLP-1 receptor agonist that’s most widely known as an antidiabetic medication because of its ability to modulate blood sugar.
The next drug in FDA trials is retatrutide.
Retatrutide is an investigational once-weekly injectable peptide being studied for obesity and type 2 diabetes that acts as a triple agonist at the receptors for GLP‑1, GIP, and glucagon.
By activating these three incretin- and glucagon-related pathways at the same time, it enhances glucose‑dependent insulin secretion, improves post‑prandial glucose control, slows gastric emptying, and increases satiety, which together help reduce caloric intake.
Concurrent glucagon receptor agonism appears to increase energy expenditure and promote fat oxidation, so patients in early trials experienced large, sustained weight loss along with better glycemic control
No comments:
Post a Comment